MedTrace Logo

Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib

NCT01562847 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 125

Last updated 2014-01-13

No results posted yet for this study

Summary

The purposes of this study are to investigate expression and frequency of ABL point mutations, a major cause of resistance in imatinib failed CML Asian patients and to find causes of Asian-specific resistance to cancer-targeting therapies through a prospective investigation of dynamics of point mutations and expression of new point mutations during nilotinib treatment.

Conditions

  • Chronic Myeloid Leukemia

Interventions

DRUG

Nilotinib

Patients will be treated with 800 mg nilotinib daily.

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Seoul St. Mary's Hospital

    lead OTHER

Principal Investigators

  • Dong-Wook Kim, MD, PhD · Seoul St. Mary's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2014-06-30
Completion
2015-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01562847 on ClinicalTrials.gov